Stock Analysis
Moderna, Inc. (MRNA) Stock Analysis
Moderna, Inc. (MRNA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Moderna, Inc. (MRNA) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
MRNA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $245.81 |
| AIQ Score | 47/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $61.21B |
| P/E Ratio (TTM) | -19.33 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$1.96 |
| Revenue (quarter ended 2026-06-30) | $145M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.9 |
| Volume | 16.14M |
| 52-week range | $22.28-$254.48 |
| RSI 14 | 69.23 |
| 50-Day SMA | $165.64 |
| 200-Day SMA | $80.51 |
| Analyst Price Target | $95.61 |
| Next Earnings | Nov 6, 2026 |
MRNAModerna, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum82
- Value34
- Quality27
- Risk resilience54
- Sentiment51
MRNA Stock Analysis Summary
Moderna, Inc. (MRNA) currently has an AIQ Score of 47/100, indicating a neutral setup. Momentum is the strongest factor at 82/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, MRNA has AIQ Score of 47/100 with Momentum base of 82/100 and fading Quality at 27/100. Wait for component alignment before adding exposure.
Momentum (82/100) leads while Quality (27/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.54% stock move · MRNA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is MRNA Bullish or Bearish Right Now?
MRNA currently has a neutral overall setup. Momentum is the strongest factor at 82/100, while Quality is weakest at 27/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 82/100.
- - Price is +48.40% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (38 vs 4).
- - Value is the current constraint at 34/100.
- - Analyst target implies -61.10% downside from the latest quote.
Current Consensus
MRNA's Technical Analysis Consensus is currently Strong Buy, with 38 buy, 3 neutral, and 4 sell votes. MRNA's 14-day RSI is 69.23, which places the stock in a constructive momentum range. MRNA's beta is 0.9, indicating market sensitivity broadly in line with the market.
What Changed in MRNA?
The largest recent change in MRNA is Momentum moving up by 7.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the MRNA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
MRNA Decision Framework
Public evidence layers, setup checks, and risk context for Moderna, Inc..
Moderna, Inc. (MRNA) Stock Analysis
Moderna, Inc. has an AIQ Score of 47/100 in a Neutral regime. Momentum is strongest at 82/100. Beta is 0.9, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | MRNA is in a Neutral AIQ regime with score 47/100. |
| Signal Conflict | The primary conflict is that momentum leads at 82/100 while quality lags at 27/100. |
| Factor Evidence | Momentum 82/100 · Value 34/100 · Quality 27/100 · Risk 54/100 · Sentiment 51/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 82/100.
Momentum is 82/100 and RSI (14) is 69.2.
MRNA is in a Neutral regime at 47/100.
Risk factor is 54/100 with beta 0.9 and annual volatility 193.78%.
Current conflict: momentum leads at 82/100 while quality lags at 27/100.
MRNA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
MRNA Fundamentals
MRNA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
MRNA Technical Analysis
MRNA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
MRNA Stock Catalysts
Track MRNA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
MRNA Dividend Analysis
MRNA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
MRNA Financial Data
MRNA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
MRNA Risk Analysis
MRNA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
MRNA Stock News
MRNA stock news, market tone, recent headlines, and catalyst context.
MRNA vs Large Cap Pharma Peers
Current peer cohort: MRNA · NVO · OGN · PFE · REGN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| MRNA Current stock | 47/100 | 34/100 | 82/100 | 54/100 | 1.67 | 193.78% | Current |
| NVO Novo Nordisk | 67/100 | 60/100 | 56/100 | 51/100 | -0.63 | 45.71% | MRNA vs NVO |
| OGN Organon & Co | 64/100 | 75/100 | 67/100 | 70/100 | 0.86 | 66.65% | MRNA vs OGN |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | MRNA vs PFE |
| REGN Regeneron Pharmaceuticals | 69/100 | 48/100 | 95/100 | 61/100 | 1.05 | 33.45% | MRNA vs REGN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching MRNA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for MRNA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
MRNA Stock FAQ
What is MRNA stock price today?
Moderna, Inc.'s current stock price is $245.81. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is MRNA bullish or bearish right now?
MRNA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is MRNA's market cap?
MRNA's market cap is $61.21B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is MRNA's current P/E ratio?
MRNA's current P/E ratio is -19.33 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is MRNA's RSI?
MRNA's 14-day RSI is 69.23 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is MRNA above its 50-day and 200-day moving averages?
MRNA is 48.40% from its 50-day SMA and 205.33% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is MRNA's next earnings date?
MRNA's next earnings date is currently listed as Nov 6, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does MRNA pay a dividend?
MRNA's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.